OncBioMune Announces Presentation at the 2018 AACR
Post# of 110
(Total Views: 485)
Posted On: 03/20/2018 1:50:07 PM
OncBioMune Announces Presentation at the 2018 AACR Annual Meeting
BATON ROUGE, La., March 20, 2018 — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, today announces that Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will present a poster at the 2018 American Association for Cancer Research (“AACR”) Annual Meeting taking place April 14 – 18, 2018 in Chicago, Illinois.
The clinical trial abstract, entitled “Interim results of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients,” highlights the safety and efficacy of ProscaVax, the Company’s novel immunotherapeutic cancer vaccine, as evidenced through data collected in the study. Based upon the impressive body of data from the Phase 1a portion of the study, OncBioMune is forgoing the planned 1b portion and moving into two, separate Phase 2 studies of ProscaVax for late-stage and early-stage prostate cancer, respectively.
The abstract also will be published online in the 2018 Proceedings of the AACR.
Details of the abstract are as follows:
Session Title: Phase I Clinical Trials 2
Session Date and Time: Monday Apr 16, 2018 8:00 AM – 12:00 PM
Session Location: McCormick Place South, Hall A, Poster Section 42
Poster Board Number: 14
http://oncbiomune.com/2018/03/20/oncbiomune-a...l-meeting/
BATON ROUGE, La., March 20, 2018 — OncBioMune Pharmaceuticals, Inc. (OTCQB:OBMP) (“OncBioMune” or the “Company”), a clinical-stage biopharmaceutical company engaged in the development of a proprietary immunotherapy cancer vaccine technology and targeted cancer therapies, today announces that Dr. Jonathan Head, Chief Executive Officer at OncBioMune, will present a poster at the 2018 American Association for Cancer Research (“AACR”) Annual Meeting taking place April 14 – 18, 2018 in Chicago, Illinois.
The clinical trial abstract, entitled “Interim results of a phase 1a clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer therapeutic vaccine in PSA defined biochemical recurrent prostate cancer patients,” highlights the safety and efficacy of ProscaVax, the Company’s novel immunotherapeutic cancer vaccine, as evidenced through data collected in the study. Based upon the impressive body of data from the Phase 1a portion of the study, OncBioMune is forgoing the planned 1b portion and moving into two, separate Phase 2 studies of ProscaVax for late-stage and early-stage prostate cancer, respectively.
The abstract also will be published online in the 2018 Proceedings of the AACR.
Details of the abstract are as follows:
Session Title: Phase I Clinical Trials 2
Session Date and Time: Monday Apr 16, 2018 8:00 AM – 12:00 PM
Session Location: McCormick Place South, Hall A, Poster Section 42
Poster Board Number: 14
http://oncbiomune.com/2018/03/20/oncbiomune-a...l-meeting/
(0)
(0)Theratechnologies Inc. (THER) Stock Research Links
Scroll down for more posts ▼